var data={"title":"Metronidazole (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metronidazole (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390030?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metronidazole-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metronidazole (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=metronidazole-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metronidazole (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770965\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Carcinogenic: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions for which this drug is indicated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770969\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>First-Metronidazole 100;</li>\n      <li>First-Metronidazole 50;</li>\n      <li>Flagyl;</li>\n      <li>Flagyl ER [DSC];</li>\n      <li>Metro;</li>\n      <li>MetroNIDAZOLE Benzo+SyrSpend</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770970\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Flagyl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771005\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Amebicide;</li>\n      <li>\n        Antibiotic, Miscellaneous;</li>\n      <li>\n        Antiprotozoal, Nitroimidazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771169\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amebiasis (acute dysentery):</b> Oral: Immediate-release tablets and capsules: 750 mg every 8 hours for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amebic liver abscess:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablets: 500 to 750 mg every 8 hours for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: 750 mg every 8 hours for 5 to 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial vaginosis or vaginitis due to</b>\n      <b>\n        <i> Gardnerella, Mobiluncus:</i></b> Oral: Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release (off-label use): 500 mg twice daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: 750 mg once daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> Oral (immediate release), IV: 500 mg every 6 hours (maximum: 4 g/day); <b>Note:</b> Initial: 1 g IV loading dose may be administered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute diverticulitis, outpatient treatment: Oral (immediate release): 500 mg every 6 to 8 hours; use in combination with a fluoroquinolone (eg, ciprofloxacin) or sulfamethoxazole and trimethoprim (Jacobs 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Complicated, community-acquired, mild to moderate (in combination with cephalosporin or fluoroquinolone): IV: 500 mg every 8 to 12 hours <b>or</b> 1.5 g every 24 hours for 4 to 7 days (provided source controlled) (Solomkin 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pelvic inflammatory disease (off-label dose):</b> Oral (immediate release):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild to moderately severe:</i> 500 mg twice daily for 14 days (may be added to a combination of a third-generation parenteral cephalosporin and doxycycline) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>With tubo-ovarian abscess:</i> 500 mg twice daily to complete at least 14 days of therapy (in combination with doxycycline following a parenteral therapy regimen)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis (index case and sex partner):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 250 mg every 8 hours for 7 days <b>or</b> 1 g twice daily for 2 doses (on same day) <b>or</b> 2 g as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alternate dosing:</i> 2 g as a single dose (preferred regimen) <b>or</b> 500 mg twice daily for 7 days (off-label dose) (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: 375 mg twice daily for 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis in HIV-infected women (off-label dose):</b> Oral (immediate release): 500 mg twice daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis, persistent or recurrent (ie, treatment failure of nitroimidazole [eg metronidazole] single-dose therapy) (index case; treatment of sex partner; off-label dose):</b> Oral (immediate release): 500 mg twice daily for 7 days. If this regimen also fails, consider 2 g once daily for 7 days (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Balantidiasis (off-label use):</b> IV, Oral (immediate release): 750 mg 3 times daily for &ge;5 days (Anagyrou 2003; Schuster 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bite wounds (animal/human) (off-label use) (IDSA [Stevens 2014]): Note:</b> Use in combination with a second- or third-generation cephalosporin, levofloxacin, or sulfamethoxazole/trimethoprim for animal bites, or in combination with ciprofloxacin or levofloxacin for human bites.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 250 to 500 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Clostridium difficile</i>-associated diarrhea (CDAD) (off-label use): Note:</b> Recent guideline recommends converting to oral vancomycin therapy if the patient does not show a clear clinical response after 5 to 7 days of metronidazole therapy (Surawicz 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate infection: Oral (immediate release): 500 mg 3 times daily for 10 to 14 days (Cohen 2010; Surawicz 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe complicated infection (no abdominal distention): IV: 500 mg 3 times daily with oral vancomycin for 10 to 14 days (Surawicz 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe complicated infection (with ileus, toxic colitis, and/or abdominal distention): IV: 500 mg 3 times daily with oral and rectal vancomycin for 10 to 14 days (Surawicz 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease, mild to moderate  (off-label use):</b> Oral (immediate release): 10 to 20 mg/kg/day (Lichtenstein 2009) or 500 mg twice daily (in combination with ciprofloxacin) (Steinhart 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dientamoeba fragilis </i></b> <b>infections (off-label use): </b> Oral (immediate release): 500 to 750 mg 3 times daily for 10 days (CDC 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Giardiasis (off-label use):</b> Oral (immediate release): 250 to 500 mg 3 times daily for 5 to 10 days (Granados 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori </i>eradication (off-label use):</b> Oral (immediate release):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">American College of Gastroenterology guidelines (Chey 2007; Chey 2017):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Clarithromycin triple regimen</i>: 500 mg 3 times daily in combination with clarithromycin 500 mg twice daily and a standard-dose or double-dose proton pump inhibitor twice daily; continue regimen for 14 days. <b>Note:</b> Avoid use of clarithromycin triple therapy in patients with risk factors for macrolide resistance (eg, prior macrolide exposure, local clarithromycin resistance rates &ge;15%, eradication rates with clarithromycin-based regimens &le;85%) (ACG [Chey 2017]; Fallone 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Bismuth quadruple regimen</i>: 250 mg 4 times daily or 500 mg 3 or 4 times daily in combination with either bismuth subsalicylate 300 mg or bismuth subcitrate 120 to 300 mg 4 times daily, tetracycline 500 mg 4 times daily, and a standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Concomitant regimen</i>: 500 mg twice daily in combination with clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, plus a standard-dose proton pump inhibitor twice daily; continue regimen for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Sequential regimen</i>: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 5 to 7 days; then follow with clarithromycin 500 mg twice daily, metronidazole 500 mg twice daily, and a standard-dose proton pump inhibitor twice daily for 5 to 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hybrid regimen</i>: Amoxicillin 1 g twice daily plus a standard-dose proton pump inhibitor twice daily for 7 days; then follow with amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, metronidazole 500 mg twice daily, and a standard-dose proton pump inhibitor twice daily for 7 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Periodontitis (associated with aggressive disease; off-label use):</b> Oral (immediate release): 250 mg every 8 hours in combination with amoxicillin for 10 days; used in addition to scaling, root planing and pocket irrigation (Silva-Senem 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pouchitis (post ileal pouch-anal anastomosis, acute treatment; off-label use):</b> Oral (immediate release): 400 to 500 mg three times daily for 7 days (Holubar 2010; Wall 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis against sexually-transmitted diseases following sexual assault (off-label use):</b> Oral (immediate release): 2 g as a single dose in combination with ceftriaxone and azithromycin (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 500 mg every 6 hours, in combination with cefotaxime or ceftriaxone for empiric therapy of polymicrobial infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer&rsquo;s labeling:</i> IV: 15 mg/kg 1 hour prior to surgical incision; followed by 7.5 mg/kg 6 and 12 hours after initial dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternate dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 500 mg within 60 minutes prior to surgical incision in combination with other antibiotics (Bratzler 2013). <b>Note:</b> Considered a recommended agent for select procedures other than colorectal surgery (off-label use) (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (for colorectal surgical prophylaxis only; immediate release; off-label use): 1 g every 3 to 4 hours for 3 doses, starting after mechanical bowel preparation the afternoon and evening before the procedure with or without additional oral antibiotics and with an appropriate IV antibiotic prophylaxis regimen (Bratzler 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical site infections (intestinal or GU tract; axilla or perineum) (off-label use):</b> IV: 500 mg every 8 hours; in combination with ceftriaxone, ciprofloxacin, or levofloxacin (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tetanus (<i>Clostridium tetani</i> infection; off-label use):</b> Oral (immediate release): 500 mg every 6 hours for 7 to 10 days in combination with supportive therapy (Ahmadsyah, 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urethritis, nongonococcal (recurrent or persistent urethritis in men who have sex with women and who live in regions where <i>T. vaginalis</i> is prevalent; off-label use):</b> Oral (immediate release): 2 g as a single dose. <b>Note:</b> Compliance with initial regimen and lack of re-exposure to an untreated sex partner should be excluded prior to use (CDC [Workowski 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771168\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=metronidazole-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metronidazole (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Some clinicians recommend using adjusted body weight in obese children. Dosing weight = IBW + 0.45 (TBW-IBW)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> [AAP 2015]): Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 30 to 50 mg/kg/<b>day</b> in divided doses 3 times daily; maximum daily dose: 2,250 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 22.5 to 40 mg/kg/<b>day</b> in divided doses 3 times daily; maximum daily dose: 1,500 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Amebiasis:</b> Infants, Children, and Adolescents: Oral: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 7 to 10 days; maximum dose: 750 mg/dose; for severe infection or extraintestinal disease, IV may be necessary (Bradley 2017; Parasitic Infections 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Appendicitis, perforated (divided dosing):</b> Children and Adolescents: IV: 30 mg/kg/<b>day</b> in divided doses 3 times daily (Emil 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Appendicitis, perforated (once-daily dosing):</b> Limited data available: Children and Adolescents: IV: 30 mg/kg/dose once daily in combination with ceftriaxone; maximum reported daily dose: 1,500 mg/<b>day</b> (Yardeni 2013); however, other pediatric trials did not report a maximum; in adult patients, a maximum daily dose of 1,500 mg/<b>day</b> for once-daily dosing is suggested (IDSA [Solomokin 2010]); in pediatric patients, once-daily metronidazole in combination with ceftriaxone has been shown to have similar efficacy as triple-combination therapy with ampicillin, clindamycin, and gentamicin (Fraser 2010; St Peter 2006; St Peter 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Balantidiasis (off-label use):</b> Infants, Children, and Adolescents: Oral: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 5 days; maximum dose: 750 mg/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection:</b> Infants, Children, and Adolescents: Oral: 10 mg/kg/dose 3 times daily. Maximum dose: 500 mg/dose (ISPD [Warady 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Clostridium difficile</i>-associated diarrhea (CDAD; off-label use):</b> Infants, Children, and Adolescents: Oral: 30 mg/kg/<b>day</b> divided every 6 hours for &ge;10 days (maximum: 2,000 mg/<b>day</b>) (<i>Red Book</i> [AAP 2015]; AAP [Schutze 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Dientamoeba fragilis (off-label use):</i></b> Infants, Children, and Adolescents: Oral: 35 to 50 mg/kg/<b>day</b> in divided doses every 8 hours for 10 days; maximum dose: 750 mg/dose (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Giardiasis (off-label use):</b> Infants, Children, and Adolescents: Oral: 15 to 30 mg/kg/<b>day</b> in divided doses every 8 hours for 5 to 7 days; maximum dose: 250 mg/dose (Bradley 2017; Gardner 2001; Granados 2012; Ross 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Helicobacter pylori</b></i>\n      <b> eradication (off-label use):</b> Children and Adolescents: Oral: 20 mg/kg/<b>day</b> in 2 divided doses for 10 to 14 days in combination with amoxicillin and a proton pump inhibitor with or without clarithromycin (maximum: 1,000 mg/<b>day</b>) (NASPGHAN/ESPGHAN [Koletzko 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inflammatory bowel disease (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Crohn disease, perianal disease; induction:</i> Children and Adolescents: Oral: 7.5 mg/kg/dose 3 times daily for 6 weeks with or without ciprofloxacin; maximum dose: 500 mg/dose (Sandhu 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Ulcerative colitis, pouchitis, persistent:</i> Children and Adolescents: Oral: 20 to 30 mg/kg/<b>day</b> in divided doses 3 times daily for 14 days with or without ciprofloxacin or oral budesonide; maximum dose: 500 mg/dose (Turner 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infection:</b> Infants, Children, and Adolescents: IV: 30 to 40 mg/kg/<b>day</b> in divided doses 3 times daily as part of combination therapy; maximum dose: 500 mg/dose (IDSA [Solomkin] 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pelvic inflammatory disease:</b> Adolescents: Oral: 500 mg twice daily for 14 days; administer with doxycycline plus a cephalosporin (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis) </b>(ISPD [Warady 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: Gastrointestinal or genitourinary procedures: Infants, Children, and Adolescents: IV: 10 mg/kg once prior to procedure in combination with cefazolin; Maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Infants, Children, and Adolescents: Oral: 10 mg/kg/dose 3 times daily. Maximum daily dose: 1,200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prophylaxis against sexually transmitted diseases following sexual assault (off-label use)</b>: Adolescents: Oral: 2,000 mg as a single dose in combination with azithromycin and ceftriaxone (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical prophylaxis (off-label use):</b> Children and Adolescents: IV: 15 mg/kg as a single dose 30 to 60 minutes prior to procedure; maximum single dose: 500 mg (IDSA/AHSP [Bratzler 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Surgical prophylaxis, colorectal</i>: Children and Adolescents: Oral: 15 mg/kg/dose every 3 to 4 hours for 3 doses, starting after mechanical bowel preparation the afternoon and evening before the procedure, with or without additional oral antibiotics and with an appropriate IV antibiotic prophylaxis regimen; maximum dose: 1,000 mg/dose (IDSA/ASHP [Bratzler] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tetanus (<i>Clostridium tetani</i> infection; off-label use):</b> Infants, Children, and Adolescents: Oral, IV: 30 mg/kg/<b>day</b> in divided doses every 6 hours for 7 to 10 days (maximum: 4,000 mg/day) (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Trichomoniasis, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;45 kg: 45 mg/kg/<b>day</b> in divided doses 3 times daily for 7 days; maximum daily dose: 2,000 mg/<b>day</b> (<i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;45 kg and Adolescents: 2,000 mg as a single dose once <b>or </b>500 mg twice daily for 7 days (CDC [Workowski 2015]; <i>Red Book</i> [AAP 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vaginosis, bacterial:</b> Children &gt;45 kg and Adolescents: Oral: 500 mg twice daily for 7 days (CDC [Workowski 2015]; <i>Red Book</i> [AAP 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771170\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771171\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer&rsquo;s labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, decreased renal function does not alter the single-dose pharmacokinetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; metronidazole metabolites may accumulate; monitor for adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ESRD requiring dialysis: Metronidazole metabolites may accumulate; monitor for adverse events. Accumulated metabolites may be rapidly removed by dialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis (IHD): If administration cannot be separated from hemodialysis, consider supplemental dose following hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Alternate dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (50% to 100%): 500 mg every 8 to 12 hours. <b>Note:</b> Dosing regimen highly dependent on clinical indication (trichomoniasis vs <i>C. difficile</i> colitis) (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of thrice weekly, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH/CVVHD/CVVHDF: 500 mg every 6 to 12 hours (or per clinical indication; dosage reduction generally not necessary)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771172\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Manufacturer&rsquo;s labeling: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary; use with caution and monitor for adverse events</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe impairment (Child-Pugh class C):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended-release tablets: Use is not recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immediate-release capsules:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Amebiasis: 375 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Trichomoniasis: 375 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immediate-release tablets, injection: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <i>Alternate dosing: </i> The pharmacokinetics of a single oral 500 mg dose were not altered in patients with cirrhosis; initial dose reduction is therefore not necessary (Daneshmend, 1982). In one study of IV metronidazole, patients with alcoholic liver disease (with or without cirrhosis), demonstrated a prolonged elimination half-life (eg, ~18 hours). The authors recommended the dose be reduced accordingly (clearance was reduced by ~62%) and the frequency may be prolonged (eg, every 12 hours instead of every 6 hours) (Lau, 1987). In another single IV dose study using metronidazole metabolism to predict hepatic function, patients classified as Child-Pugh class C demonstrated a half-life of ~21.5 hours (Muscara, 1995). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771210\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flagyl: 375 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 375 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metro: 500 mg (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (100 mL); 5 mg/mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Metronidazole 50: 50 mg/mL (150 mL) [contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Metronidazole 100: 100 mg/mL (150 mL) [contains saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MetroNIDAZOLE Benzo+SyrSpend: 50 mg/mL (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flagyl: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg, 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flagyl ER: 750 mg [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770972\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26841822\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral solution contains 28 mEq of sodium/gram of metronidazole.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">First-Metronidazole and MetroNIDAZOLE Benzo+SyrSpend oral suspensions are a compounding kits. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49944876\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the United States. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flagyl: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771184\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Infuse intravenously over 30 to 60 minutes. Avoid contact of drug solution with equipment containing aluminum.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Immediate-release tablets and capsules may be administered with food to minimize stomach upset. Extended-release tablets should be administered on an empty stomach (1 hour before or 2 hours after meals); do not split, crush, or chew. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771015\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Amebiasis:</b> Oral immediate-release tablet and capsule: Treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: When used for amebic liver abscess, may be used concurrently with percutaneous needle aspiration when it is clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anaerobic bacterial infections (caused by </b>\n      <b>\n        <i>Bacteroides </i></b>\n      <b>spp.</b>\n      <b>\n        <i>, </i></b>\n      <b>including the</b>\n      <b>\n        <i> B. fragilis</i></b>\n      <b> group):</b> Oral immediate-release tablet, capsule, and injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacterial septicemia:</b> Treatment of bacterial septicemia (also caused by <i>Clostridium </i>spp.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone and joint infections:</b> Treatment (adjunctive therapy) of bone and joint infections</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS Infections:</b> Treatment of CNS infections, including meningitis and brain abscess</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis:</b> Treatment of endocarditis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gynecologic infections:</b> Treatment of gynecologic infections including endometritis, endomyometritis, tubo-ovarian abscess, or postsurgical vaginal cuff infection (also caused by <i>Clostridium </i>spp., <i>Peptococcus </i>spp., <i>Peptostreptococcus </i>spp., and <i>Fusobacterium </i>spp.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infections:</b> Treatment of intra-abdominal infections, including peritonitis, intra-abdominal abscess and liver abscess (also caused by <i>Clostridium </i>spp., <i>Eubacterium </i>spp., <i>Peptococcus </i>spp., and <i>Peptostreptococcus </i>spp.)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Lower respiratory tract infections:</b> Treatment of lower respiratory tract infections, including pneumonia, empyema and lung abscess</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections:</b> Treatment of skin and skin structure infections (also caused by <i>Clostridium </i>spp., <i>Peptococcus </i>spp., <i>Peptostreptococcus </i>spp., and <i>Fusobacterium </i>spp.)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial vaginosis:</b> Oral extended-release tablet: Treatment of bacterial vaginosis in nonpregnant women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Surgical prophylaxis (colorectal surgery):</b> Injection: Preoperative, intraoperative, and postoperative prophylaxis to reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery classified as contaminated or potentially contaminated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis:</b> Oral immediate-release tablet, capsule: Treatment of infections caused by <i>Trichomonas vaginalis</i>, including treatment of asymptomatic sexual partners</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469421\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Balantidiasis (adults); Balantidiasis (children/adolescents); Bite wounds (animal/human); Clostridium difficile infection (adults); Crohn disease, mild to moderate; Dientamoeba fragilis (adults); Giardiasis; Helicobacter pylori eradication; Periodontitis; Pouchitis (acute); Prophylaxis against sexually-transmitted diseases following sexual assault; Skin and soft tissue necrotizing infections; Surgical infection prophylaxis (preoperative); Surgical site infections; Tetanus (adults); Tetanus (children); Urethritis, nongonococcal (persistent and recurrent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770967\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MetroNIDAZOLE may be confused with mebendazole, meropenem, metFORMIN, methotrexate, metoclopramide, miconazole</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771037\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (10% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Vaginitis (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Metallic taste (9%), dizziness (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Genital pruritus (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (4%), diarrhea (4%), xerostomia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysmenorrhea (3%), urine abnormality (3%), urinary tract infection (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Bacterial infection (7%), candidiasis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Flu-like symptoms (6%), upper respiratory tract infection (4%), pharyngitis (3%), sinusitis (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain, facial edema, flattened T-wave on ECG, flushing, palpitations, peripheral edema, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Aseptic meningitis, ataxia, brain disease, chills, confusion, convulsions, depression, disulfiram-like reaction (with alcohol), drowsiness, dysarthria, hypoesthesia, insomnia, irritability, malaise, numbness, paresthesia, peripheral neuropathy, psychosis, seizure, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythematous rash, hyperhidrosis, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Decreased libido</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal cramps, abdominal distress, anorexia, constipation, decreased appetite, dysgeusia, glossitis, hairy tongue, pancreatitis (rare), proctitis, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Cystitis, dark urine (rare), dyspareunia, dysuria, urinary incontinence, urine discoloration, vaginal dryness, vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Agranulocytosis, eosinophilia, leukopenia, neutropenia (reversible), thrombocytopenia (reversible, rare)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes, jaundice, severe hepatotoxicity (patients with Cockayne syndrome)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis, hypersensitivity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: DRESS syndrome, serum sickness-like reaction (joint pains)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Inflammation at injection site (IV), injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Abnormal eye movements (saccadic), nystagmus, optic neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Polyuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea, nasal congestion, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever, lesion (central nervous system, reversible)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771023\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to metronidazole, nitroimidazole derivatives, or any component of the formulation; pregnant patients (first trimester) with trichomoniasis; use of disulfiram within the past 2 weeks; use of alcohol or propylene glycol-containing products during therapy or within 3 days of therapy discontinuation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Active neurological disorders; history of blood dyscrasia; hypothyroidism; hypoadrenalism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771024\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinogenic: <b>[US Boxed Warning]: Possibly carcinogenic based on animal data.</b> Reserve use for conditions described in Use; unnecessary use should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Severe neurological disturbances, including aseptic meningitis (may occur within hours of a dose), cerebellar symptoms (ataxia, dizziness, dysarthria, nystagmus, saccadic pursuit), convulsive seizures, encephalopathy, optic neuropathy, and peripheral neuropathy (usually symmetric and of sensory type) have been reported. Encephalopathy is associated with widespread lesions on brain MRI; cerebellar toxicity is accompanied by T2 flair lesions within the dentate nuclei seen on MRI. Cerebellar toxicity may occur concurrently with encephalopathy, peripheral neuropathy, or seizures. CNS symptoms and CNS lesions are generally reversible within days to weeks of discontinuation of therapy; peripheral neuropathy symptoms may be prolonged after discontinuation. Monitor for neurologic symptoms and discontinue therapy if any abnormal neurologic symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Candidiasis infection (known or unknown) may be more prominent during metronidazole treatment, antifungal treatment required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: Use with caution in patients with or history of blood dyscrasias; agranulocytosis, leukopenia, and neutropenia have occurred. Monitor CBC with differential at baseline, during and after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cockayne syndrome: Severe hepatotoxicity/acute hepatic failure (has been fatal) has been reported with systemic metronidazole in patients with Cockayne syndrome; onset is rapid after initiation of treatment. Use metronidazole only after risk vs benefit assessment and if there are no appropriate alternatives in patients with Cockayne syndrome. Obtain LFTs prior to treatment initiation, within the first 2 to 3 days of initiation, frequently during therapy, and after treatment is complete. Discontinue treatment if elevated LFTs occur and monitor until LFTs return to baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment due to potential accumulation; dosage adjustment recommended in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment or ESRD due to potential accumulation. Accumulated metabolites may be rapidly removed by hemodialysis; supplemental doses may be needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage-form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablets: Do not use in patients with severe hepatic impairment (Child-Pugh class C) unless benefit outweighs risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: Use injection with caution in patients with heart failure, edema, or other sodium-retaining states, including corticosteroid treatment due to high sodium content. In patients receiving continuous nasogastric secretion aspiration, sufficient metronidazole may be removed in the aspirate to cause a reduction in serum levels.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Guidelines recommend the use of oral metronidazole for initial treatment of mild to moderate <i>C. difficile</i> infection and the use of oral vancomycin for initial treatment of severe <i>C. difficile</i> infection (with or without IV metronidazole depending on the presence of complications). May treat recurrent mild to moderate infection once with oral metronidazole; avoid use beyond first reoccurrence. (Cohen 2010; Surawicz 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Abdominal cramps, nausea, vomiting, headaches, and flushing have been reported with oral and injectable metronidazole and concomitant alcohol consumption (disulfiram-like reactions); avoid alcoholic beverages or products containing propylene glycol during oral or injectable therapy and for at least 3 days after therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771042\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771043\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9589&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Busulfan: MetroNIDAZOLE (Systemic) may increase the serum concentration of Busulfan.  Management: The toxic effects of busulfan may be greatly increased with concomitant use of metronidazole. This combination should probably be avoided when possible.  If these agents must be used together, increased monitoring for busulfan toxicity is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: MetroNIDAZOLE (Systemic) may increase serum concentrations of the active metabolite(s) of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, metronidazole may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). In particular, the risk for CNS toxicities such as psychosis may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Dronabinol. Specifically, metronidazole may produce severe intolerance to the alcohol contained in the dronabinol oral solution. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluorouracil (Systemic): MetroNIDAZOLE (Systemic) may increase the serum concentration of Fluorouracil (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lithium. MetroNIDAZOLE (Systemic) may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Lopinavir. Specifically, the combination of metronidazole and lopinavir/ritonavir solution, which contains 42% alcohol, may result in a disulfiram-like reaction. MetroNIDAZOLE (Systemic) may enhance the arrhythmogenic effect of Lopinavir.  Management: Avoid the concomitant use of lopinavir/ritonavir and metronidazole if possible. If these agents are used concomitantly, monitor for QTc prolongation/arrhythmia and if the lopinavir/ritonavir solution is used, development of a disulfiram-like reaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mebendazole: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Particularly the risk for Stevens-Johnson syndrome or toxic epidermal necrolysis may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: MetroNIDAZOLE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, metronidazole may decrease concentrations of the active metabolite of mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of MetroNIDAZOLE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of MetroNIDAZOLE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May enhance the adverse/toxic effect of MetroNIDAZOLE (Systemic). Specifically, the combination of ritonavir oral solution or ritonavir soft gelatin capsule, both of which contain alcohol, and metronidazole may result in a disulfiram-like reaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: MetroNIDAZOLE (Systemic) may increase serum concentrations of the active metabolite(s) of Tegafur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: MetroNIDAZOLE (Systemic) may enhance the adverse/toxic effect of Tipranavir. A disulfiram-like reaction may occur due to the alcohol contained in tipranavir capsules. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vecuronium: MetroNIDAZOLE (Systemic) may enhance the neuromuscular-blocking effect of Vecuronium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): MetroNIDAZOLE (Systemic) may increase the serum concentration of Vitamin K Antagonists.  Management: Consider alternatives to concomitant therapy with these agents.  If concomitant therapy cannot be avoided, consider reducing the dose of the vitamin K antagonist and monitor for increased INR/bleeding.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771047\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Peak antibiotic serum concentration lowered and delayed, but total drug absorbed not affected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771019\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use of metronidazole during the first trimester of pregnancy is contraindicated by the manufacturer for the treatment of trichomoniasis. Metronidazole crosses the placenta. Cleft lip with or without cleft palate has been reported following first trimester exposure to metronidazole; however, most studies have not shown an increased risk of congenital anomalies or other adverse events to the fetus following maternal use during pregnancy. Because metronidazole was carcinogenic in some animal species, concern has been raised whether metronidazole should be used during pregnancy. Available studies have not shown an increased risk of infant cancer following metronidazole exposure during pregnancy; however, the ability to detect a signal for this may have been limited.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Metronidazole pharmacokinetics are similar between pregnant and nonpregnant patients (Amon 1981; Visser 1984; Wang 2011). Bacterial vaginosis has been associated with adverse pregnancy outcomes; metronidazole is recommended for the treatment of symptomatic bacterial vaginosis in pregnant patients (CDC [Workowski 2015]). Vaginal trichomoniasis has been also associated with adverse pregnancy outcomes; use of metronidazole for this indication during the first trimester is contraindicated by the manufacturer; however, some guidelines note treatment can be given at any stage of pregnancy (CDC [Workowski 2015]). Metronidazole may also be used for the treatment of giardiasis in pregnant women (some sources recommend second and third trimester administration only) (Gardner 2001; HHS [OI adult 2015]) and symptomatic amebiasis during pregnancy (HHS [OI adult 2015]; Li 1996). Short courses may be used for the treatment of pouchitis or perianal disease in pregnant women with inflammatory bowel disease (avoid use in the first trimester) (van der Woude 2015).The use of other agents is preferred when treatment is needed during pregnancy for <i>Clostridium difficile</i> (Surawicz 2013) or <i>Helicobacter pylori</i> (Mahadevan 2006). Consult current guidelines for appropriate use in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771022\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metronidazole and its active hydroxyl metabolite are present in breast milk at concentrations similar to maternal plasma concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The relative infant dose (RID) of metronidazole is 13.7% to 22.9% when calculated using the highest average breast milk concentration reported and compared to an oral infant therapeutic dose of 30 to 50 mg/kg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10%; when an RID is &gt;25% breastfeeding should generally be avoided (Anderson 2016; Ito 2000). Using the highest average milk concentration (45.8 mcg/mL), the estimated daily infant dose via breast milk is 6.87 mg/kg/day. This milk concentration was obtained following a single maternal dose of oral metronidazole 2,000 mg; the authors estimated the infant would have been exposed to metronidazole 21.8 mg over the first 24 hours after the dose (Erickson 1981).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The highest average milk concentration occurred 2 to 4 hours after a single oral maternal dose; the half-life in breast milk was ~9 to 10 hours (Erickson 1982). Metronidazole and its active metabolite can be detected in the serum of nursing infants (Gray 1961; Heisterberg 1983; Passmore 1988).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Loose stools, oral and perianal <i>Candida </i>growth, and oral thrush have been reported in breastfeeding infants exposed to metronidazole (Passmore 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The manufacturer warns of the risk of carcinogenicity in patients exposed to metronidazole based on animal studies; theoretically, this risk is also present in breastfeeding infants exposed to metronidazole via breast milk. Therefore, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. Some guidelines note if metronidazole is given, breastfeeding should be withheld for 12 to 24 hours after a single dose (CDC [Workowski 2015]; WHO 2002); alternatively, the mother may pump and discard breast milk for 24 hours after taking the last metronidazole dose. Breastfeeding should be avoided in women requiring treatment with metronidazole for inflammatory bowel disease (van der Woude 2015). Use of other agents is preferred when treating breastfeeding women for <i>Clostridium difficile</i> infection (Surawicz 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771183\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immediate-release tablets and capsules may be administered with food to minimize stomach upset. Extended-release tablets should be taken on an empty stomach (1 hour before or 2 hours after meals). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium: Injectable dosage form may contain sodium. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Use of ethanol is contraindicated during therapy and for 3 days after therapy discontinuation.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25872498\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor CBC with differential at baseline, during, and after prolonged or repeated courses of therapy. Monitor LFTs in patients with Cockayne syndrome. Closely monitor elderly patients and patients with severe hepatic impairment or ESRD for adverse reactions. Observe patients carefully if neurologic symptoms occur and consider discontinuation of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771129\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">After diffusing into the organism, interacts with DNA to cause a loss of helical DNA structure and strand breakage resulting in inhibition of protein synthesis and cell death in susceptible organisms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771131\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: To bile, seminal fluid, bone, liver, and liver abscesses, lung and vaginal secretions; crosses blood-brain barrier; saliva and CSF concentrations similar to those in plasma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (30% to 60%) to several metabolites including an active hydroxyl metabolite which maintains activity ~30% to 65% of the parent compound (Lamp 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates &lt;7 days (Jager-Roman 1982): Within first week of life, more prolonged than with lower GA: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GA 28 to 30 weeks: 75.3 &plusmn; 16.9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GA 32 to 35 weeks: 35.4 &plusmn; 1.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">GA 36 to 40 weeks: 24.8 &plusmn; 1.6 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates &ge;7 days: ~22.5 hours (Upadhyaya 1988) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents: 6 to 10 hours (Lamp 1999) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: Immediate release: 1 to 2 hours; Extended release: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (unchanged drug and metabolites: 60% to 80%; ~20% of total as unchanged drug); feces (6% to 15%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771212\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Flagyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg (50): $717.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (MetroNIDAZOLE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">375 mg (50): $614.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Metro Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 0.74% (100 mL): $2.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (MetroNIDAZOLE in NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL 0.79% (100 mL): $2.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 0.79 (100 mL): $1.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (MetroNIDAZOLE Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (100 mL): $2.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (First-Metronidazole 100 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (150 mL): $127.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (First-Metronidazole 50 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (150 mL): $84.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (MetroNIDAZOLE Benzo+SyrSpend Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (120 mL): $306.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Flagyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (50): $515.35</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (50): $920.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (MetroNIDAZOLE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (100): $43.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (500): $345.75</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961987\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agometrol (TZ);</li>\n      <li>Amevan (EC);</li>\n      <li>Amgyl (LK);</li>\n      <li>Amotrex (BD);</li>\n      <li>Amrizole (QA);</li>\n      <li>Anaemetro (JP);</li>\n      <li>Anaerobex (AT);</li>\n      <li>Anaerobyl (ZW);</li>\n      <li>Anazol (AE, QA);</li>\n      <li>Anerobizol (PH);</li>\n      <li>Antizoal (PH);</li>\n      <li>Ao Ke An (CN);</li>\n      <li>Arilin (DE);</li>\n      <li>Asiazole (TH);</li>\n      <li>Axagyl (PH);</li>\n      <li>Biatron (ID);</li>\n      <li>Camezol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Clont (DE);</li>\n      <li>Clovizole (PH);</li>\n      <li>Dazolin (ID);</li>\n      <li>Deflamon (IT);</li>\n      <li>Dequazol Oral (PE);</li>\n      <li>Dirozyl (BD);</li>\n      <li>Dumozol (AE, BH, CY, JO, KW, SA);</li>\n      <li>Efloran (CZ, UA);</li>\n      <li>Elyzol (FI);</li>\n      <li>Endazole (PH);</li>\n      <li>Entizol (CZ);</li>\n      <li>Farnat (ID);</li>\n      <li>Fentiazol (PY);</li>\n      <li>Fladex (ID);</li>\n      <li>Flagesol (UY);</li>\n      <li>Flagizole (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Flagyl (AR, AU, BB, BE, BG, BH, BR, CH, CL, CO, CU, CY, EC, EG, ES, FR, GB, GR, HK, ID, IE, IL, IN, IS, JO, KR, KW, LB, LK, LU, MT, NL, NO, NZ, PE, PH, PK, PT, QA, RO, RU, SA, SG, SI, TH, TR, TW, VE, VN, ZW);</li>\n      <li>Flahil (UA);</li>\n      <li>Flasinyl (KR);</li>\n      <li>Flazol (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Flazole (LV);</li>\n      <li>Fogyl (MY);</li>\n      <li>Frotin (HK, MY, TW);</li>\n      <li>Fu Shu Da (CN);</li>\n      <li>Gynoplix (HK);</li>\n      <li>Helmizol (BR);</li>\n      <li>Klont (MT);</li>\n      <li>Medazol (HR);</li>\n      <li>Metason (LK);</li>\n      <li>Metazol (ZA);</li>\n      <li>Metressa (UA);</li>\n      <li>Metris (ZW);</li>\n      <li>Metrogyl (AU, ET);</li>\n      <li>Metrolag (AE, BF, BH, BJ, CH, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, SA, SC, SD, SL, SN, SY, TN, TW, TZ, UG, YE, ZM, ZW);</li>\n      <li>Metrolex (TH);</li>\n      <li>Metronidazole IV (AU, NZ);</li>\n      <li>Metronide (AU);</li>\n      <li>Metrorex (ET);</li>\n      <li>Metrozin (CO);</li>\n      <li>Molazol (ID);</li>\n      <li>Nalox (AR);</li>\n      <li>Narobic (ZA);</li>\n      <li>Negazole (ET);</li>\n      <li>Nidazole (AE, BH, JO, QA, SA);</li>\n      <li>Nirmet (TH);</li>\n      <li>Normet (ET);</li>\n      <li>Norzol (MT);</li>\n      <li>Novazole (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Patryl (PH);</li>\n      <li>Progyl (ID);</li>\n      <li>Protozol (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Protozole (PH);</li>\n      <li>Qualigyl (HK);</li>\n      <li>Qugyl (BD);</li>\n      <li>Rodazid (PH);</li>\n      <li>Ronazol (ID);</li>\n      <li>Sharizole (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Sicabact (ET);</li>\n      <li>Supplin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Trichex (AT);</li>\n      <li>Trizele (KR);</li>\n      <li>Trogiar (ID);</li>\n      <li>Trogyl (ID);</li>\n      <li>Unigo (HK, TH);</li>\n      <li>Vadazol (ID);</li>\n      <li>Vertisal (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Zidoval (AU);</li>\n      <li>Zol (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3928066\"></a>Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. <i>Br Med J</i>. 1985;291(6496):648-650.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/3928066/pubmed\" target=\"_blank\" id=\"3928066\">3928066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allen LV Jr, Erickson MA 3rd. Stability of Ketoconazole, Metolazone, Metronidazole, Procainamide Hydrochloride, and Spironolactone in Extemporaneously Compounded Oral Liquids. <i>Am J Health Syst Pharm</i>. 1996;53(17):2073-2078.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"AAP.2015\"></a>American Academy of Pediatrics (AAP). Guidelines for Treatment of Sexually Transmitted Infections. <i>American Academy of Pediatrics. </i>2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/AAP.2015/pubmed\" target=\"_blank\" id=\"AAP.2015\">AAP.2015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amon I, Amon K, Franke G, et al. Pharmacokinetics of metronidazole in pregnant women. <i>Chemotherapy</i>. 1981;27(2):73-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/7471904/pubmed\" target=\"_blank\" id=\"7471904\">7471904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12827655\"></a>Anagyrou K, Petrikkos GL, Suller MT, et al. Pulmonary Balantidium coli infection in a leukemic patient. <i>Am J Hematol</i>. 2003;73(3):180-183.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/12827655/pubmed\" target=\"_blank\" id=\"12827655\">12827655</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bartlett JG and Perl TM, &quot;The New <i>Clostridium difficile</i>- What Does it Mean?&quot; <i>N Engl J Med</i>, 2005, 353(23):2503-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/16322604/pubmed\" target=\"_blank\" id=\"16322604\">16322604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belliveau PP, Nightingale CH, and Quintilani R, &ldquo;Stability of Cefotaxime Sodium and Metronidazole in 0.9% Sodium Chloride Injection or in Ready-to-Use Metronidazole Bags,&rdquo; <i>Am J Health Syst Pharm</i>, 1995, 52(14):1561-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/7552904/pubmed\" target=\"_blank\" id=\"7552904\">7552904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bratzler DW, Dellinger EP, Olsen KM, et al, &ldquo;Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,&rdquo; <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/23327981/pubmed\" target=\"_blank\" id=\"23327981\">23327981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brodgen RN, Heel RC, Speight TM, et al, &ldquo;Metronidazole in Anaerobic Infections: A Review of Its Activity, Pharmacokinetics and Therapeutic Use,&rdquo; <i>Drugs</i>, 1978, 16(5):387-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/363399/pubmed\" target=\"_blank\" id=\"363399\">363399</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cantu JM and Carcia-Cruz D, &ldquo;Midline Facial Defect as a Teratogenic Effect of Metronidazole,&rdquo; <i>Birth Defects</i>, 1982, 18:85-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. <i>MMWR Morb Mortal Wkly Rep</i>. 2012;61(31):590-594.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/22874837/pubmed\" target=\"_blank\" id=\"22874837\">22874837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Center for Disease Control and Prevention (CDC), Parasites &ndash; Dientamoeba fragilis; Resources for Health Professionals. Updated December, 2012. <a href=\"http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html\" target=\"_blank\">http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html</a>. Accessed April 10, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/28071659/pubmed\" target=\"_blank\" id=\"28071659\">28071659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroenterol</i>, 2007 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen SH, Gerding DN, Johnson S, et al, &ldquo;Clinical Practice Guidelines for <i>Clostridium difficile</i> Infection in Adults: 2010 Update by the Society for healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA), <i>Infect Control Hosp Epidemiol</i>, 2010, 31(5):431-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/20307191/pubmed\" target=\"_blank\" id=\"20307191\">20307191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Committee on Adolescence, American Academy of Pediatrics, &ldquo;Sexual Assault and the Adolescent,&rdquo; <i>Pediatrics</i>, 1994, 94(5):761-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/7936916/pubmed\" target=\"_blank\" id=\"7936916\">7936916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coronado BE, Opal SM, and Yoburn DC, &ldquo;Antibiotic-Induced D-Lactic Acidosis,&rdquo; <i>Ann Intern Med</i>, 1995, 122(11):839-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/7741368/pubmed\" target=\"_blank\" id=\"7741368\">7741368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daneshmend TK, Homeida M, Kaye CM, Elamin AA, Roberts CJ. Disposition of oral metronidazole in hepatic cirrhosis and in hepatosplenic schistosomiasis. <i>Gut</i>. 1982;23(10):807-813.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/7117899/pubmed\" target=\"_blank\" id=\"7117899\">7117899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Parasitic Infections,&rdquo; <i>Treatment Guidelines From the Medical Letter</i>, 2013, 1(Suppl):e1-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eisenberg L, Suchow R, Coles RS, et al. The effects of metronidazole administration on clinical and microbiologic parameters of periodontal disease. <i>Clin Prev Dent.</i> 1991;13(1):28-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/1860284/pubmed\" target=\"_blank\" id=\"1860284\">1860284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emil S, Laberge JM, Mikhail P, et al. Appendicitis in children: a ten-year update of therapeutic recommendations. <i>J Pediatr Surg</i>. 2003;38(2):236-242.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/12596112/pubmed\" target=\"_blank\" id=\"12596112\">12596112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. <i>Obstet Gynecol</i>. 1981;57(1):48-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/7454176 /pubmed\" target=\"_blank\" id=\"7454176 \">7454176 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/27102658/pubmed\" target=\"_blank\" id=\"27102658\">27102658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fekety R and Shah AB, &ldquo;Diagnosis and Treatment of <i>Clostridium difficile</i> Colitis,&rdquo; <i>JAMA</i>, 1993, 269(1):71-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/8416409/pubmed\" target=\"_blank\" id=\"8416409\">8416409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flagyl (metronidazole) [prescribing information]. New York, NY: Pfizer; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flagyl capsules (metronidazole) [prescribing information]. New York, NY: Pfizer; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flagyl ER (metronidazole) [prescribing information]. New York, NY: Pfizer; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flagyl (metronidazole) [product monograph]. Pointe-Claire, Quebec, Canada: Odan Laboratories LTD; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraser JD, Aguayo P, Leys CM, et al. A complete course of intravenous antibiotics vs a combination of intravenous and oral antibiotics for perforated appendicitis in children: a prospective, randomized trial. <i>J Pediatr Surg</i>. 2010;45(6):1198-1202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/20620320/pubmed\" target=\"_blank\" id=\"20620320\">20620320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freeman CD, Klutman NE, and Lamp KC, &ldquo;Metronidazole. A Therapeutic Review and Update,&rdquo; <i>Drugs</i>, 1997, 54(5):679-708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/9360057/pubmed\" target=\"_blank\" id=\"9360057\">9360057</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gardner TB, Hill DR. Treatment of giardiasis. <i>Clin Microbiol Rev</i>. 2001;14(1):114-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/11148005 /pubmed\" target=\"_blank\" id=\"11148005 \">11148005 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23235648\"></a>Granados CE, Reveiz L, Uribe LG, Criollo CP. Drugs for treating giardiasis (Review). <i>Cochrane Database Syst Rev</i>. 2012;12:CD007787. doi:10.1002/14651858.CD007787.pub2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/23235648/pubmed\" target=\"_blank\" id=\"23235648\">23235648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gray MS, Kane PO, Squires S. Further observations on metronidazole (Flagyl&reg;). <i>Br J Vener Dis</i>. 1961;37:278-279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/13901320/pubmed\" target=\"_blank\" id=\"13901320\">13901320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hampson JP, &ldquo;The Use of Metronidazole in the Treatment of Malodorous Wounds,&rdquo; <i>J Wound Care</i>, 1996, 5(9):421-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/8954436/pubmed\" target=\"_blank\" id=\"8954436\">8954436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heisterberg L, Branebjerg PE. Blood and milk concentrations of metronidazole in mothers and infants. <i>J Perinat Med</i>. 1983; 11(2):114-120.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/6854509/pubmed\" target=\"_blank\" id=\"6854509\">6854509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herrera D, Sanz M, Jepsen S, et al, &quot;A Systematic Review on the Effect of Systemic Antimicrobials as an Adjunct to Scaling and Root Planing in Periodontitis Patients,&quot; <i>J Clin Periodontol</i>, 2002, 29(Suppl 3):136-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/12787214/pubmed\" target=\"_blank\" id=\"12787214\">12787214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA). April 2015. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf%20\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20556748\"></a>Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis (Review). <i>Cochrane Database Syst Rev</i>. 2010; 6:CD001176. doi:10.1002/14651858.CD001176.pub2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/20556748/pubmed\" target=\"_blank\" id=\"20556748\">20556748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Israel DM and Hassall E, &ldquo;Treatment and Long-Term Follow-up of <i>Helicobacter pylori</i>-Associated Duodenal Ulcer Disease in Children,&rdquo; <i>J Pediatr</i>, 1993, 123(1):53-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/8320625/pubmed\" target=\"_blank\" id=\"8320625\">8320625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobs DO. Clinical practice. Diverticulitis. <i>N Engl J Med</i>. 2007;357(20):2057-2066.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/18003962/pubmed\" target=\"_blank\" id=\"18003962\">18003962</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jager-Roman E, Doyle PE, Baird-Lambert J, Cvejic M, Buchanan N. Pharmacokinetics and tissue distribution of metronidazole in the new born infant. <i>J Pediatr</i>. 1982;100(4):651-654.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/7062220/pubmed\" target=\"_blank\" id=\"7062220\">7062220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly CP, Pothoulakis C, and LaMont JT, &ldquo;<i>Clostridium difficile</i> Colitis,&rdquo; <i>N Engl J Med</i>, 1994, 330(4):257-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/8043060/pubmed\" target=\"_blank\" id=\"8043060\">8043060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koletzko S, Jones NL, Goodman KJ, et al; H pylori Working Groups of ESPGHAN and NASPGHAN. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. <i>J Pediatr Gasroenterol Nutr</i>. 2011;53(2):230-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/21558964/pubmed\" target=\"_blank\" id=\"21558964\">21558964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam S and Bank S, &ldquo;Hepatotoxicity Caused by Metronidazole Overdose,&rdquo; <i>Ann Intern Med</i>, 1995, 122(10):803.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamp KC, Freeman CD, Klutman NE, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of the Nitroimidazole Antimicrobials,&rdquo; <i>Clin Pharmacokinet</i>, 1999, 36(5):353-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/10384859/pubmed\" target=\"_blank\" id=\"10384859\">10384859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lau AH, Chang CW, and Sabatini S, &ldquo;Hemodialysis Clearance of Metronidazole and its Metabolites,&rdquo; <i>Antimicrob Agents Chemother</i>, 1986, 29(2):235-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/3717930/pubmed\" target=\"_blank\" id=\"3717930\">3717930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li E, Stanley SL Jr. Protozoa. Amebiasis. <i>Gastroenterol Clin North Am</i>. 1996; 25(3):471-492.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/8863036 /pubmed\" target=\"_blank\" id=\"8863036 \">8863036 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loesche WJ, Giordano JR, Hujoel P, et al, &quot;Metronidazole in Periodontitis: Reduced Need for Surgery,&quot; <i>J Clin Periodontol</i>, 1992, 19(2):103-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/1602034/pubmed\" target=\"_blank\" id=\"1602034\">1602034</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loesche WJ, Schmidt E, Smith BA, et al, &quot;Effects of Metronidazole on Periodontal Treatment Needs,&quot; <i>J Periodontol</i>, 1991, 62(4):247-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/2037955/pubmed\" target=\"_blank\" id=\"2037955\">2037955</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lorber B, &quot;Update in Infectious Diseases,&quot; <i>Ann Intern Med</i>, 2006, 145:356-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ludwig E, Csiba A, Magyar T, et al, &ldquo;Age-Associated Pharmacokinetic Changes of Metronidazole,&rdquo; <i>Int J Clin Pharmacol Ther Toxicol</i>, 1983, 21(2):87-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/6840930/pubmed\" target=\"_blank\" id=\"6840930\">6840930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. <i>Gastroenterology</i>. 2006; 131(1):283-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/16831611 /pubmed\" target=\"_blank\" id=\"16831611 \">16831611 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metronidazole injection in sodium chloride [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/28631728/pubmed\" target=\"_blank\" id=\"28631728\">28631728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan I. Metronidazole treatment in pregnancy. <i>Int J Gynaecol Obstet</i>. 1978; 15(6):501-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/29796/pubmed\" target=\"_blank\" id=\"29796\">29796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mottet C, Vader JP, Felley C, et al. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): results of a multidisciplinary international expert panel-EPACT II. <i>J Crohns Colitis</i>. 2009; 3(4):257-263.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/21172284 /pubmed\" target=\"_blank\" id=\"21172284 \">21172284 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Muscar&aacute; MN, Pedrazzoli J Jr, Miranda EL, et al, &quot;Plasma Hydroxy-Metronidazole/Metronidazole Ratio in Patients With Liver Disease and in Healthy Volunteers,&quot; <i>Br J Clin Pharmacol</i>, 1995, 40(5):477-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/8703652/pubmed\" target=\"_blank\" id=\"8703652\">8703652</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Passmore CM, McElnay JC, Rainey EA, et al, &quot;Metronidazole Excretion in Human Milk and its Effect on the Suckling Neonate,&quot; <i>Br J Clin Pharmacol</i>, 1988, 26(1):45-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/3203060/pubmed\" target=\"_blank\" id=\"3203060\">3203060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ralph ED, &ldquo;Clinical Pharmacokinetics of Metronidazole,&rdquo; <i>Clin Pharmacokinet</i>, 1983, 8:43-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/6340904/pubmed\" target=\"_blank\" id=\"6340904\">6340904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross AG, Olds GR, Cripps AW, Farrar JJ, McManus DP. Enteropathogens and chronic illness in returning travelers. <i>N Engl J Med</i>. 2013;368(19):1817-1825.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/23656647/pubmed\" target=\"_blank\" id=\"23656647\">23656647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. <i>J Pediatr Gastroenterol Nutr</i>. 2010;50(Suppl 1):S1-S13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/23656647/pubmed\" target=\"_blank\" id=\"23656647\">23656647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18854484\"></a>Schuster FL, Ramirez-Avila L. Current world status of Balantidium coli. <i>Clin Micro Rev</i>. 2008;21(4):626-638.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/18854484/pubmed\" target=\"_blank\" id=\"18854484\">18854484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schutze GE, Willoughby RE; Committee on Infectious Diseases, American Academy of Pediatrics. Clostridium difficile infection in infants and children. <i>Pediatrics</i>. 2013;131(1):196-200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/23277317/pubmed\" target=\"_blank\" id=\"23277317\">23277317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23297772\"></a>Silva-Senem MX, Heller D, Varela VM, Torres MC, Feres-Filho EJ, Colombo AP. Clinical and microbiological effects of systemic antimicrobials combined to an anti-infective mechanical debridement for the management of aggressive periodontitis: a 12-month randomized controlled trial. <i>J Clin Periodontol</i>. 2013;40(3):242-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/23297772/pubmed\" target=\"_blank\" id=\"23297772\">23297772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smogyi A, Kong C, Sabto J, et al, &ldquo;Disposition and Removal of Metronidazole in Patients Undergoing Haemodialysis,&rdquo; <i>Eur J Clin Pharmacol</i>, 1983, 25:683-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/6662167/pubmed\" target=\"_blank\" id=\"6662167\">6662167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12105831\"></a>Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. <i>Gastroenterology</i>. 2002;123(1):33-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/12105831/pubmed\" target=\"_blank\" id=\"12105831\">12105831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    St Peter SD, Little DC, Calkins CM, et al. A simple and more cost-effective antibiotic regimen for perforated appendicitis. <i>J Pediatr Surg</i>. 2006;41(5):1020-1024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/16677904/pubmed\" target=\"_blank\" id=\"16677904\">16677904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    St Peter SD, Tsao K, Spilde TL, et al. Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial. <i>J Pediatr Surg</i>. 2008;43(6):981-985.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/18558169/pubmed\" target=\"_blank\" id=\"18558169\">18558169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of <i>Clostridium difficile</i> infections. <i>Am J Gastroenterol</i>. 2013;108(4):478-498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/23439232/pubmed\" target=\"_blank\" id=\"23439232\">23439232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sutherland L, Singleton J, Sessions J, et al, &ldquo;Double Blind, Placebo Controlled Trial of Metronidazole in Crohn&rsquo;s Disease,&rdquo; <i>Gut</i>, 1991, 32(9):1071-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/1916494/pubmed\" target=\"_blank\" id=\"1916494\">1916494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo; <i>Am J Gastroenterol</i>, 2005, 100(10):2324-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/16181387/pubmed\" target=\"_blank\" id=\"16181387\">16181387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Treatment of <i>Clostridium difficile</i> Diarrhea,&rdquo; <i>Med Lett Drugs Ther</i>, 1989, 31(803):94-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/2796843/pubmed\" target=\"_blank\" id=\"2796843\">2796843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(3):340-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/22773060/pubmed\" target=\"_blank\" id=\"22773060\">22773060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. <i>J Pediatr Surg</i>. 1988;23(3):263-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/3357144/pubmed\" target=\"_blank\" id=\"3357144\">3357144</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Woude CJ, Ardizzone S, Bengtson MB, et al; European Crohn&rsquo;s and Colitis Organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. <i>J Crohns Colitis</i>. 2015;9(2):107-124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/25602023 /pubmed\" target=\"_blank\" id=\"25602023 \">25602023 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varela VM, Heller D, Silva-Senem MX, et al, &quot;Systemic Antimicrobials Adjunctive to a Repeated Mechanical and Antiseptic Therapy for Aggressive Periodontitis: A 6-Month Randomized Controlled Trial,&quot; <i>J Periodontol</i>, 2011, 82(8):1121-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/21235333/pubmed\" target=\"_blank\" id=\"21235333\">21235333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visser AA and Hundt HK, &quot;The Pharmacokinetics of a Single Intravenous Dose of Metronidazole in Pregnant Patients,&quot; <i>J Antimicrob Chemother</i>, 1984, 13(3):279-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/6725177 /pubmed\" target=\"_blank\" id=\"6725177 \">6725177 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wall GC, Shirmer LL, Anliker LE, Tigges AE. Pharmacotherapy for acute pouchitis. <i>Ann Pharmacother</i>. 2011;45(9):1127-1137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/21775695/pubmed\" target=\"_blank\" id=\"21775695\">21775695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang X, Nanovskaya TN, Zhan Y, et al, &quot;Pharmacokinetics of Metronidazole in Pregnant Patients With Bacterial Vaginosis,&quot; <i>J Matern Fetal Neonatal Med</i>, 2011, 24(3):444-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/20608802/pubmed\" target=\"_blank\" id=\"20608802\">20608802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;32(Suppl 2):S32-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-systemic-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yardeni D, Kawar B, Siplovich L, et al. Single daily dosing of ceftriaxone and metronidazole is as safe and effective as ampicillin, gentamicin and metronidazole for non-operative management of complicated appendicitis in children. <i>Pediat Therapeut</i>. 2013;3:5.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9589 Version 273.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8770965\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8770969\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8770970\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8771005\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8771169\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8771168\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8771170\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8771171\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8771172\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8771210\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8770972\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F26841822\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49944876\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8771184\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8771015\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469421\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8770967\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8771037\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8771023\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8771024\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8771042\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8771043\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8771047\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8771019\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8771022\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8771183\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25872498\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8771129\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8771131\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8771212\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961987\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9589|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metronidazole-systemic-patient-drug-information\" class=\"drug drug_patient\">Metronidazole (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=metronidazole-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Metronidazole (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}